Vetoryl for Dogs: Trilostane and Cushing's Treatment

If your dog has been diagnosed with hyperadrenocorticism — commonly called Cushing's disease — your veterinarian has likely discussed Vetoryl (trilostane) as a treatment option. Here's the direct answer to the most common question: Vetoryl is an FDA-approved prescription medication that treats Cushing's disease in dogs by inhibiting the enzyme 3-beta-hydroxysteroid dehydrogenase (3β-HSD), effectively reducing the adrenal glands' ability to produce cortisol. It is currently the only medication approved specifically for canine Cushing's disease and has become the standard of care since receiving FDA approval in 2008.

This is not a medication to start, adjust, or discontinue without direct veterinary supervision. Incorrect dosing can cause life-threatening adrenal insufficiency. Always follow your veterinarian's monitoring schedule precisely.

The Endocrine Science: How Vetoryl Works in the Canine Body

To understand why Vetoryl works, you need to understand the hypothalamic-pituitary-adrenal (HPA) axis — the hormone cascade that governs cortisol production in all mammals, including dogs.

In dogs with Cushing's disease, this feedback loop is broken. Approximately 80-85% of cases are pituitary-dependent hyperadrenocorticism (PDH), where a benign pituitary tumor (adenoma) continuously pumps out ACTH regardless of cortisol levels. The remaining 15-20% are adrenal-dependent (ADH), caused by a cortisol-secreting adrenal tumor that operates independently of pituitary signals.

Vetoryl's active ingredient, trilostane, is a competitive inhibitor of the 3β-HSD enzyme. By blocking this enzyme in the adrenal cortex, trilostane interrupts the biochemical assembly line that converts cholesterol-derived precursors into active cortisol. The drug doesn't fix the underlying tumor — it manages the downstream effect: excessive cortisol production.

Research published in the Journal of Veterinary Internal Medicine (2015, Galac et al.) demonstrated that trilostane treatment achieved adequate cortisol control in approximately 70-85% of dogs within the first 30 days when dosed according to body weight protocols. A follow-up study in the Merck Veterinary Manual confirms trilostane as the preferred medical management for both PDH and ADH when surgery is not an option.

Evolutionary Context: Why the Canine HPA Axis Is Vulnerable to Dysregulation

The HPA axis evolved in ancestral canids as a survival mechanism. Wolves in the wild face episodic stressors — prey encounters, territorial disputes, food scarcity — that require rapid cortisol spikes to mobilize glucose, suppress non-essential functions (reproduction, digestion), and sharpen alertness. Once the stressor passes, cortisol drops back to baseline via intact negative feedback.

Domestic dogs inherited this same neuroendocrine architecture, but their stressor profile has shifted dramatically. Modern dogs experience chronic, low-grade stressors (separation anxiety, noise phobia, confinement) rather than acute physical threats. While this doesn't directly cause Cushing's disease — which is driven by neoplastic growth — the evolutionary context explains why the canine adrenal system is so potent and why its dysregulation produces such dramatic, multi-systemic effects.

Cortisol touches nearly every organ system: it increases hepatic gluconeogenesis (liver produces more glucose), promotes protein catabolism in skeletal muscle (muscle wasting), redistributes fat (pot-bellied appearance), suppresses immune function (recurrent infections), and thins the dermis (hair loss, fragile skin). When a pituitary tumor hijacks this system, the result is a dog whose body is perpetually in a biochemical fight-or-flight state with no off switch.

Vetoryl Dosing, Monitoring, and What to Expect

Vetoryl comes in hard gelatin capsules in six strengths: 10 mg, 30 mg, 60 mg, 120 mg, and (in some markets) 180 mg. The 2026 pricing landscape places these capsules in the following ranges:

Costs vary based on pharmacy source (online vs. veterinary clinic), compounding options, and whether once-daily or twice-daily dosing is prescribed. Many endocrinologists now favor twice-daily dosing at lower per-dose amounts because it produces more stable cortisol levels throughout the 24-hour cycle and reduces peak-trough fluctuations that can cause symptom breakthrough in the evening hours.

The Monitoring Protocol You Cannot Skip

Vetoryl is not a "set and forget" medication. The ACTH stimulation test — the gold standard monitoring tool — measures your dog's adrenal reserve capacity at specific intervals. Here is the standard monitoring schedule endorsed by the American Veterinary Medical Association and veterinary endocrinology specialists:

• Day 10-14: First ACTH stimulation test + electrolyte panel (sodium, potassium). Check for over-suppression.
• Day 30: Second ACTH stimulation test + full chemistry panel. Dose adjustment likely.
• Day 90: Third ACTH stimulation test. By now, most dogs reach stable dosing.
• Every 3-6 months thereafter: Ongoing ACTH stimulation + chemistry panels for life.

Each ACTH stimulation test typically costs $150-$350 at a general practice and $250-$500 at a specialty clinic. Budget-conscious owners should discuss monitoring frequency with their veterinarian — some protocols allow extending to 6-month intervals once stable dosing is confirmed over two consecutive tests.

Breed Variations and Risk Factors in Cushing's Disease

While Cushing's disease can affect any dog, certain breeds show statistically higher prevalence, likely due to genetic predisposition to pituitary or adrenal tumor formation:

The median age of Cushing's diagnosis across all breeds is approximately 10-11 years. Female dogs are slightly overrepresented in most epidemiological studies, though the sex difference is modest. Importantly, iatrogenic Cushing's — caused by prolonged corticosteroid administration for allergies, autoimmune disease, or other conditions — can occur at any age and in any breed. If your dog has been on prednisone, dexamethasone, or methylprednisolone for more than 3-4 weeks, discuss tapering protocols with your veterinarian.

Common Misconceptions About Vetoryl and Cushing's Treatment

Practical Daily Life With a Dog on Vetoryl

Managing a dog on long-term Vetoryl involves consistent routines and awareness of subtle changes that signal the need for dose adjustment.

Drug Interactions to Know

Vetoryl has several clinically significant drug interactions. Inform your veterinarian of all medications, including over-the-counter products:

• Ketoconazole: Both drugs inhibit steroidogenesis. Concurrent use dramatically increases risk of adrenal insufficiency. If your dog was previously on ketoconazole, a washout period of 5-7 days is typically recommended before starting Vetoryl.
• Mitotane (Lysodren): This older Cushing's drug destroys adrenal tissue permanently. Transitioning from mitotane to Vetoryl requires a 4-6 week washout and an ACTH stimulation test confirming some adrenal function has returned.
• Spironolactone: Used for cardiac or hepatic conditions, this potassium-sparing diuretic can compound the hyperkalemia risk if Vetoryl causes even mild adrenal suppression.
• ACE inhibitors (enalapril, benazepril): Similar potassium-retention concern. Monitor electrolytes more frequently when combining.
• NSAIDs (carprofen, meloxicam): No direct interaction with trilostane, but Cushing's dogs already have increased GI ulcer risk from mucosal thinning. Use NSAIDs cautiously and with gastroprotectants if needed.

Physiological Mechanisms: What Happens at the Cellular Level

Trilostane is a synthetic steroid analogue — specifically, it is 4α,5α-epoxy-17β-hydroxy-3-oxoandrostane-2α-carbonitrile. Its molecular structure mimics the natural substrate of 3β-HSD, allowing it to bind competitively to the enzyme's active site without being converted into a downstream product.

The inhibition is reversible and competitive, meaning that when trilostane blood levels drop (approximately 6-12 hours after dosing), the enzyme gradually resumes normal function. This reversibility is what makes Vetoryl safer than mitotane, which causes irreversible adrenal cortical cell death. However, it also means that consistent, timed dosing is essential — missed doses allow cortisol to spike back to pre-treatment levels within 24-48 hours.

At the cellular level, trilostane primarily affects the zona fasciculata (middle layer of the adrenal cortex, responsible for cortisol production) and, to a lesser extent, the zona glomerulosa (outer layer, responsible for aldosterone). This is why electrolyte monitoring — specifically sodium and potassium — is part of every follow-up panel. If the zona glomerulosa is excessively suppressed, aldosterone production drops, leading to sodium loss and potassium retention, mimicking Addison's disease.

Research from the Merck Veterinary Manual notes that approximately 2-5% of dogs on trilostane develop clinically significant hypoaldosteronism, requiring dose reduction or discontinuation. This risk is higher in dogs receiving concurrent medications that affect potassium balance.

When Cortisol Changes Signal a Deeper Problem

Not all dogs with Cushing's symptoms have a tumor. Atypical Cushing's disease — also called sex-hormone imbalance or adrenal hyperplasia — involves elevated adrenal sex hormones (progesterone, androstenedione, estradiol) rather than cortisol alone. Standard ACTH stimulation tests may show normal cortisol results while the dog exhibits classic Cushing's signs (alopecia, pot belly, PU/PD).

If your dog has clinical signs of Cushing's but normal ACTH stimulation results, ask your veterinarian about an adrenal sex hormone panel or a low-dose dexamethasone suppression test (LDDST), which is more sensitive for detecting early or atypical cases. The LDDST involves three blood draws over 8 hours and costs approximately $200-$400.

Additionally, approximately 10-20% of dogs with pituitary-dependent Cushing's have macroadenomas (tumors >10 mm) that can compress surrounding brain tissue. Signs that your dog's pituitary tumor may be large include:

• Sudden behavioral changes, disorientation, or apparent confusion
• Head pressing against walls or furniture
• Vision changes or apparent blindness
• Seizure activity (new onset in a senior dog)
• Rapid progression of symptoms despite adequate Vetoryl dosing

These neurological signs warrant advanced imaging (MRI or CT scan, typically $1,500-$3,000) and referral to a veterinary neurologist or oncologist. Radiation therapy for pituitary macroadenomas has shown response rates of 70-80% in reducing tumor size and improving neurological symptoms, based on protocols described in the AVMA-indexed veterinary oncology literature.

Frequently Asked Questions About Vetoryl for Dogs

Why do dogs develop Cushing's disease in the first place?

Cushing's disease in dogs is primarily caused by spontaneous benign tumors — either in the pituitary gland (80-85% of cases) or the adrenal gland (15-20%). The exact cause of tumor formation is not fully understood, though genetic predisposition, age-related cellular changes, and possibly chronic HPA axis stimulation all play roles. Unlike in humans, diet and lifestyle do not appear to be significant risk factors for canine Cushing's.

Can dogs live a normal lifespan on Vetoryl?

Yes. Studies report median survival times of 2.0-2.5 years from diagnosis for dogs with pituitary-dependent Cushing's treated with trilostane, with many dogs living 3-5+ years when well-monitored. Dogs with small pituitary microadenomas and no comorbidities (diabetes, pancreatitis) often have the best long-term outcomes. The primary mortality risk is not Cushing's itself but complications: diabetes mellitus (which Cushing's can trigger), urinary tract infections, pancreatitis, and thromboembolic events.

How do dogs process trilostane differently from humans?

Dogs metabolize trilostane primarily through hepatic pathways, with a half-life of approximately 1-2 hours in canines (compared to 3-4 hours in humans). However, the biological effect on cortisol suppression lasts 8-12 hours due to sustained enzyme binding at the adrenal level. Dogs also have proportionally larger adrenal glands relative to body weight compared to humans, which influences dosing calculations. The drug is excreted through both renal and fecal routes.

What does it mean when my dog seems worse after starting Vetoryl?

Transient worsening in the first 1-2 weeks can occur as the body adjusts to lower cortisol levels. Dogs accustomed to chronically elevated cortisol may temporarily show lethargy, reduced appetite, or mild GI upset as their metabolic set-point recalibrates. However, if symptoms are severe (vomiting, collapse, profound weakness), this may indicate over-suppression and requires immediate veterinary attention. Never adjust the dose yourself — contact your veterinarian.

Is it normal for my dog to still drink a lot on Vetoryl?

Some residual polydipsia is common even with well-controlled Cushing's. The target is not complete normalization of all symptoms but rather meaningful reduction (typically 50-70% reduction in water intake) combined with ACTH stimulation results in the acceptable range (post-ACTH cortisol 2-7 µg/dL, though target ranges vary by laboratory). If your dog's drinking remains at pre-treatment levels after 30 days, dose adjustment is likely needed.

How is Vetoryl different from the older treatment, mitotane?

Mitotane (Lysodren, o,p'-DDD) is an adrenocorticolysis agent — it physically destroys cells in the zona fasciculata. The effect is partially irreversible, making dose errors more dangerous. Vetoryl's competitive enzyme inhibition is fully reversible, giving veterinarians more control. Mitotane requires a loading phase with careful observation for signs of adrenal insufficiency, followed by weekly then monthly maintenance doses. While mitotane is less expensive ($15-$40/month), Vetoryl has largely replaced it as first-line therapy due to its wider safety margin and more predictable dosing response.